文献速递预防保健、筛查与疫苗

Comirnaty新冠疫苗接种患者决策辅助工具的研发

Development of a patient decision aid for COVID-19 vaccination with the Comirnaty vaccine.
PubMed 文献 · Fam Pract · 2022-01-01

法国全科教师学院依据IPDAS标准研发Comirnaty疫苗接种患者决策辅助工具,基于文献综述和17名患者访谈设计初稿,经专家组alpha测试和14次接种前咨询的beta测试。文献综述仅识别出一项关于Comirnaty有效性和安全性的随机试验。工具帮助患者识别自身风险因素并提供疫苗获益、风险及mRNA技术说明。

要点

  • 该工具依据IPDAS标准研发,用于初级保健中Comirnaty接种的共享决策。
  • 工具第一部分帮助患者识别自身风险因素,第二部分提供疫苗获益、风险及未知数据。
  • 文献综述仅识别出一项关于Comirnaty有效性和安全性的随机试验。

核心结论

  • 成功研发了可用于初级保健场景、针对Comirnaty疫苗接种共享决策的患者决策辅助工具。

研究设计与样本

  • 依据IPDAS标准研发患者决策辅助工具,初稿基于文献综述和17名患者半结构访谈。
  • 初稿经患者专家组和医师专家组alpha测试,最终在14次接种前咨询中进行beta测试。
  • 指导小组全程参与,患者支持组织、社区团体和法国国家卫生管理局参与研发过程。

主要发现

  • 文献综述仅识别出一项关于Comirnaty有效性和安全性的随机试验。
  • 工具第一部分帮助患者识别自身风险因素。
  • 工具第二部分提供疫苗获益与风险、未知数据及mRNA疫苗技术说明。

临床怎么用

  • 可在初级保健的接种前咨询中使用该工具,支持患者就Comirnaty疫苗接种做出知情选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SARS-CoV-2 has been responsible for a pandemic since the beginning of 2020. Vaccine arrival brings a concrete solution to fight the virus. However, vaccine hesitancy is high. In France, the first available vaccine was Comirnaty from Pfizer-BioNTech. Shared decision-making, based on tools such as patient decision aids (PtDAs), can help patients make an informed choice about vaccination with Comirnaty. OBJECTIVE: The French College of Teachers in General Practice (CNGE) aimed to create a PtDA for people who have to decide whether they will receive the Comirnaty vaccine. METHODS: Development of the PtDA was performed according to the International Patient Decision Aids Standards (IPDAS). The initial design was based on a literature review and semistructured interviews with 17 patients to explore and clarify patients' expectations. A first draft of the PtDA was then alpha tested by a patient expert group and a physician expert group. The PtDA was finally beta tested in 14 prevaccine consultations. A steering group was consulted throughout the work. Patient support, community groups and the French National Authority for Health (HAS) were involved in the development process. RESULTS: A literature review identified one randomized trial on Comirnaty efficacy and safety. The first part of the PtDA allows patients to identify their own risk factors. The second part of the PtDA provides information on vaccination: benefits and risks, unknown data, and technical explanations about the mRNA vaccine. CONCLUSIONS: We developed a PtDA to be used in primary care settings for shared decision-making regarding vaccination with Comirnaty.

来源:Fam Pract,查看原文。版权归原作者所有。

引用

  1. Vincent YM, Frachon A, Allaire A, et al. Development of a patient decision aid for COVID-19 vaccination with the Comirnaty vaccine. Fam Pract. 2022. PMID: 34849748. doi:10.1093/fampra/cmab156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。